Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing ophthalmic formulations for the treatment of retinal diseases. The company's core mission is to redefine the standard of care for these conditions by providing an on-label, quality-controlled treatment option, particularly for wet age-related macular degeneration (wet AMD). Headquartered in Iselin, New Jersey, the company aims to enhance patient outcomes by addressing unmet medical needs in ophthalmology.

The company's primary product candidate is ONS-5010, branded as LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), an investigational ophthalmic formulation of bevacizumab. This product is being developed for use in retinal indications, including wet AMD, diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). LYTENAVA™ (bevacizumab gamma) has received Marketing Authorization from the European Commission and the MHRA for wet AMD and commenced commercial launch in Germany and the UK in June 2025. In the United States, ONS-5010/LYTENAVA™ is investigational, with a Biologics License Application (BLA) resubmitted to the FDA.

Recent notable developments include the appointment of Bob Jahr as CEO in July 2025, with Lawrence A. Kenyon continuing as CFO. The company has been actively navigating regulatory pathways, including the resubmission of its BLA to the FDA in February 2025. However, the FDA issued a Complete Response Letter (CRL) in December 2025, requesting confirmatory evidence of efficacy. Outlook Therapeutics completed a Federal Dispute Resolution (FDR) meeting with the FDA in April 2026 to address these concerns. The company is transitioning to a commercial-stage entity with initial European sales, and its future market positioning is significantly tied to potential FDA approval in the U.S., which would establish LYTENAVA™ as the first and only FDA-approved ophthalmic formulation of bevacizumab.